Conditions: Hepatitis C Human Immunodeficiency Virus
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 65
Healthy volunteers: no

Brief summary:
Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds at week 4.

The primary hypothesis of this study is that the subset of patients with a Rapid Viral Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.

Detailed description:

Arms:
arm 1: All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.

Interventions: intervention 1: Boceprevir
Intervention descriptions: intervention 1: None

Protocol document: